YK11 10mg

YK11 is a specialized research reagent utilized primarily to investigate the biochemical pathways of selective androgen receptor modulation and the regulation of myostatin inhibition. As a partial agonist of the androgen receptor and a potent inducer of follistatin, it is a fundamental tool for exploring the limits of muscle cell proliferation and osteoblastic differentiation. Dragon Pharma provides YK11 at a purity level of 99%+, specifically for use in in-vitro laboratory experiments and preclinical animal models.

Overview

In the realm of musculoskeletal biology and molecular endocrinology, YK11 has become a primary instrument for investigators exploring the intersection of androgen signaling and growth-limiting proteins. Known scientifically as (17$\alpha$,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester, this compound offers a unique steroidal-backbone SARM profile that distinguishes it from non-steroidal analogs. Dragon Pharma provides YK11 at a minimum purity of 99%, ensuring that researchers have access to a high-grade Research Compound capable of producing reproducible and accurate data in complex biological models.

As scientific inquiry into muscle-wasting disorders, sarcopenia, and advanced bone-regeneration pathways expands, the need for dual-action reagents like YK11 has grown. This expanded profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of YK11.

Molecular Characteristics and Chemical Profile

The structural integrity of YK11 is what allows it to bind to the androgen receptor (AR) while simultaneously stimulating the production of follistatin. Unlike traditional androgens, YK11 acts as a gene-selective modulator, specifically targeting the myogenic regulatory factors.

• Chemical Identity: YK11
• Molecular Formula: C25H34O6
• Molecular Weight: 430.54 g/mol
• Purity: >99% (HPLC and Mass Spectrometry verified)
• Form: Crystalline powder / Lyophilized powder
• Manufacturer: Dragon Pharma

Research Applications

The compound is utilized in various scientific investigative domains, including:

• Myostatin Inhibition: Mapping the pathways by which increased follistatin levels neutralize myostatin activity.
• Skeletal Muscle Myogenesis: Investigating the induction of myogenic differentiation factors like MyoD and myogenin.
• Osteoblastic Mineralization: Studying the enhancement of bone-specific alkaline phosphatase and osteocalcin levels.
• Androgen Receptor Selectivity: Assessing the partial agonistic effects on AR-mediated transcriptional activity.
• Cellular Senescence: Evaluating the impact of follistatin upregulation on the lifespan and regenerative capacity of satellite cells.

Pathway and Mechanistic Context

The core value of YK11 in a laboratory setting is its ability to manipulate the Follistatin-Myostatin Axis independently of native hormonal fluctuations. In a natural physiological state, myostatin acts as a "braking system" for muscle growth.

The Myogenic Potentiation Axis

Upon binding to the AR by YK11, the cell initiates a global shift in protein expression. Unlike other SARMs, YK11 triggers the release of follistatin, a glycoprotein that binds to and inhibits myostatin, effectively removing the genetic ceiling on muscle cell growth.

Key Mechanistic Shifts:

• Follistatin Induction: YK11 facilitates a dose-dependent increase in follistatin mRNA expression, providing a framework for studying hyper-anabolic states.
• Androgenic Selectivity: It maintains anabolic signaling in muscle and bone tissues with significantly reduced impact on prostate weight in preclinical models compared to DHT.
• Bone Matrix Optimization: Researchers use YK11 to observe how the activation of the AKT/protein kinase B pathway enhances the mineralization of the bone matrix.

Primary Research Applications

1. Sarcopenia and Geriatric Muscle Resilience

YK11 is heavily utilized in studies involving age-related muscle atrophy. Statistics indicate that sarcopenia affects approximately 10% of adults over age 60, with the prevalence rising to 50% in those over age 80. Demographic data shows that Non-Hispanic Black men often possess 10-15% more skeletal muscle mass than Caucasian counterparts, yet all groups face significant functional declines with age. YK11 provides a unique framework for investigating the reversal of this decline through the dual mechanisms of AR activation and myostatin suppression.

2. Oncology and Cancer-Induced Cachexia

Known in research circles for its "pro-myogenic" potential, YK11 is used to observe how tissues adapt to the extreme catabolic stress of oncology models. Research indicates that cachexia is responsible for up to 30% of cancer-related deaths; YK11 is investigated for its ability to maintain lean tissue mass when traditional anabolic signaling is compromised.

3. Bone Fragility and Osteoporosis

In metabolic research, YK11 is studied for its ability to improve bone density. Preclinical studies have shown that YK11 can increase the expression of osteogenic markers by over 200% in cell cultures, aiding research into the management of severe osteopenia and fracture recovery.

Form and Analytical Testing

At Dragon Pharma, the commitment to scientific accuracy begins with a rigorous manufacturing process. YK11 is produced under strict laboratory conditions to ensure the compound remains stable and potent.

• Stability and Purity: The compound is optimized for long-term stability, removing synthesis byproducts that could interfere with sensitive follistatin or myostatin assays.
• Rigorous Analytical Verification: To guarantee a purity level of 99% or higher, every batch undergoes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to confirm that the chemical signature matches the verified YK11 profile.